Amylin Byetta Antibodies Could Be Root Of Response Variability In Pivotals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Patients showing a poor response to Lilly/Amylin’s type 2 diabetes treatment Byetta have high numbers of antibodies to the incretin mimetic, FDA review documents suggest.